We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hospira Announces Epogen/Procrit Biosimilar Application, Fourth in U.S.
Hospira Announces Epogen/Procrit Biosimilar Application, Fourth in U.S.
Hospira has submitted a BLA for anemia drug Retacrit, a proposed biosimilar to Amgen’s Epogen and Janssen’s Procrit — making it the fourth company to announce submission of a biosimilar application to the FDA.